Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 0.72 |
| ▸ | ROCK2 known ✓ | O75116 | 6/20 | 0.71 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.69 |
| ▸ | PARP1 known ✓ | P09874 | 1/20 | 0.69 |
| ▸ | PRKCE known ✓ | Q02156 | 3/20 | 0.65 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.65 |
| ▸ | PRKD1 known ✓ | Q15139 | 3/20 | 0.65 |
| ▸ | PRKD3 known ✓ | O94806 | 2/20 | 0.59 |
| ▸ | PRKCG known ✓ | P05129 | 2/20 | 0.59 |
| ▸ | PRKCB known ✓ | P05771 | 2/20 | 0.59 |
| ▸ | PRKCA known ✓ | P17252 | 2/20 | 0.59 |
| ▸ | PRKCH known ✓ | P24723 | 2/20 | 0.59 |
| ▸ | PRKCI known ✓ | P41743 | 2/20 | 0.59 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.59 |
| ▸ | PRKCZ known ✓ | Q05513 | 2/20 | 0.59 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.59 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.59 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.59 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1848494 | 1.00 | MAPK1 (1.00) | MAPK1LMNAMAPTGMNNPMP22 | |
| SCHEMBL2869228 | 0.99 | CYP3A4 (1.00) | MAPK1LMNAMAPTGMNNPMP22 | |
| Hydrochloric Acid SCHEMBL1986979 | 0.96 | CYP3A4 (0.95) | MAPK1LMNAMAPTGMNNPMP22 | |
| Hydrochloric Acid SCHEMBL30237215 | 0.85 | LMNA (1.00) | MAPK1LMNAMAPTGMNNPMP22 | |
| Hydrochloric Acid SCHEMBL29651499 | 0.85 | LMNA (1.00) | MAPK1LMNAMAPTGMNNPMP22 | |
| Hydrochloric Acid SCHEMBL3691324 | 0.85 | LMNA (1.00) | MAPK1LMNAMAPTGMNNPMP22 | |
| SCHEMBL14207926 | 0.85 | KMT2A (0.76) | MAPK1LMNAMAPTGMNNPMP22 | |
| SCHEMBL3244492 | 0.84 | CYP3A4 (0.74) | MAPK1LMNAMAPTGMNNPMP22 | |
| SCHEMBL10719519 | 0.84 | SMN1; SMN2 (0.80) | MAPK1LMNAMAPTGMNNPMP22 | |
| SCHEMBL1271163 | 0.84 | ROCK1 (1.00) | MAPK1LMNAMAPTGMNNPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4732908-A2 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-12533359-B2 | Method for preventing hair loss | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-01-27 | — | — | US | claimed |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | claimed |
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | claimed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| CN-119614426-A | Composite starter and application thereof in preparation of ectoin | 山东兰束生物科技有限公司 | 2025-03-14 | — | — | CN | claimed |
| EP-4512480-A2 | CANCER TREATMENTS USING COMBINATIONS OF CDK AND ERK INHIBITORS | Biomed Valley Discoveries, Inc. (US) | 2025-02-26 | — | — | EP | claimed |
| CN-119302371-A | Preparation method of double-fermentation fruit juice tea beverage and fruit juice tea beverage | 喜悦物产食品科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20220273770-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-09-01 | — | — | US | claimed |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-08-11 | — | — | US | claimed |
| CN-110799245-B | Compositions and methods for treating cancer with atypical BRAF mutations | 生物医学谷探索股份有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | claimed |
| EP-4003405-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | Merck Sharp & Dohme Corp. (US) | 2022-06-01 | — | — | EP | claimed |
| EP-3993764-A1 | METHOD FOR PREVENTING HAIR LOSS | Icahn School of Medicine at Mount Sinai (US) | 2022-05-11 | — | — | EP | claimed |
| EP-3980052-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-04-13 | — | — | EP | claimed |
| EP-3082957-B1 | CANCER TREATMENTS USING COMBINATIONS OF PI3K/AKT PATHWAY AND ERK INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-04-06 | — | — | EP | claimed |
| CN-114088830-A | Method for detecting isomer in 4- (3-fluorobenzyloxy) benzaldehyde | 石家庄四药有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-3082800-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2022-02-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | ROCK1 3400/4885ROCK2 3963/4885KCNH2 3235/4885 |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, IRS1, INSR | ROCK1 3400/4885ROCK2 3963/4885KCNH2 3235/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | ROCK1 2960/4885ROCK2 4077/4885KCNH2 2940/4885 |
| US-20220273770-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | IRS1, GPR119, INSR | ROCK1 2566/4885ROCK2 3515/4885KCNH2 3826/4885 |
| US-12533359-B2 | Method for preventing hair loss | MYLK, MYLK3, MYLK2 | ROCK1 1070/4885ROCK2 514/4885KCNH2 1787/4885 |
| US-20220249509-A1 | METHOD FOR PREVENTING HAIR LOSS | MYLK3, MYLK4, MYLK | ROCK1 34/4885ROCK2 39/4885KCNH2 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.